

Special Issue

AIDS Vaccine 2014

Message from the Guest Editor

A few decades after the discovery of human immunodeficiency viruses as the causal pathogens for AIDS, an effective AIDS vaccine has not been successfully developed to curb the global epidemic of HIV infections. HIV employs many tactics to prevent induction of protective T and B cell immune responses. Facing such a huge challenge, we hope this "AIDS Vaccine" special issue will offer a platform for publication of cutting-edge results in the AIDS vaccine research field.

Previous Special Issue published in *Viruses*: "[AIDS Vaccine](#)" Prof. Dr. Feng Gao

Guest Editor

Prof. Dr. Feng Gao

1. Institute of Molecular and Medical Virology, School of Medicine, Jinan University, 601 Huangpu Ave. West, Guangzhou 510632, China
2. Department of Medicine, Duke University Medical Center, 303 Research Dr., DUMC 102359, Durham, NC 27710, USA

Deadline for manuscript submissions

closed (15 July 2014)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/2094

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).